SEC.gov | SEC Charges Biotech Company and CEO With Fraud Concerning COVID-19 Blood Testing Device
FOR IMMEDIATE RELEASE Washington D.C., Dec. 18, 2020 — The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick blood test. The SEC temporarily suspended trading in Decision Diagnostics' securities on April 23, 2020. The SEC's complaint alleges that Decision Diagnostics and Berman ...
Source: sec.gov